The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…

BioMarin Pharmaceutical (Nasdaq:BMRN) saw its share price dip 3.5% in mid-day trading to $88.30 after announcing a reorganization. The company said it would cut 4% of its workforce, or approximately 120 positions, to save cash. In a press release, BioMarin cited the potential launch of Roctavian as one of the reasons beyond the layoff. The…

The pandemic has heightened interest in COVID-19 therapies, sometimes stealing attention from other pharmaceutical breakthroughs. But the pandemic has also served as a reminder that investment in new drugs can pay dividends while leading to a greater societal appreciation for the industry. A 2019 study published in International Health concluded that pharmaceuticals that have launched…